Targeting non-bromodomain chromatin readers
- PMID: 31582844
- DOI: 10.1038/s41594-019-0290-2
Targeting non-bromodomain chromatin readers
Abstract
Chromatin regulatory proteins are increasingly recognized as potential new drug targets. Many of these proteins harbor one or more so called 'reader domains' that recognize covalent modifications of lysine and arginine residues, typically on histones, which mediate specific interactions within chromatin. Here we review recent progress in the discovery of drug-like small molecules that antagonize the function of methyl-lysine and methyl-arginine reader domains (Royal family, plant homeodomain (PHD) and WD40 domains) as well as the acyl-lysine-binding YEATS domain.
References
-
- Arrowsmith, C. H., Bountra, C., Fish, P. V., Lee, K. & Schapira, M. Epigenetic protein families: a new frontier for drug discovery. Nat. Rev. Drug Discov. 11, 384–400 (2012). - DOI
-
- Jeltsch, A., Broche, J. & Bashtrykov, P. Molecular processes connecting DNA methylation patterns with DNA methyltransferases and histone modifications in mammalian genomes. Genes 9, E566 (2018). - DOI
-
- Zaware, N. & Zhou, M.-M. Bromodomain biology and drug discovery. Nat. Struct. Mol. Biol. https://doi.org/10.1038/s41594-019-0309-8 (2019).
-
- Maurer-Stroh, S. et al. The Tudor domain ‘Royal Family’: Tudor, plant Agenet, Chromo, PWWP and MBT domains. Trends Biochem. Sci. 28, 69–74 (2003). - DOI
-
- Gayatri, S. & Bedford, M. T. Readers of histone methylarginine marks. Biochim. Biophys. Acta 1839, 702–710 (2014). - DOI
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
